Most natural carotenoids display poor aqueous solubility and tend to form aggregates in solution.
JPET #87114

Introduction
The generation of reactive oxygen species during the reintroduction of blood flow to a previously ischemic area is one of the main mechanisms underlying myocardial reperfusion injury. Damage occurs when endogenous free radical scavenging mechanisms are overwhelmed or are themselves adversely affected by the ischemic insult (Park and Lucchesi, 1999) . The ability of reactive oxygen species to alter myocardial function has been demonstrated in vitro as well as in vivo (Jolly et al., 1984; Bolli et al., 1989) . The exposure of the heart to free radical generating systems or the addition of hydrogen peroxide (H 2 O 2 ) to the perfusion medium is associated with alterations in cardiac function and biochemical changes similar to those observed in the damaged myocardium as a result of ischemia and reperfusion. Therefore it has been hypothesized that administration of antioxidant compounds will attenuate myocardial damage attributed to reperfusion injury.
Carotenoids are a group of naturally-occurring pigments that demonstrate antioxidant capabilities related to their physiochemical structures (Britton, 1995) . These compounds are efficient antioxidants and are known to be physical quenchers of singlet oxygen as well as chainterminators of lipid peroxidation in cell membranes and intracellular membrane structures (Devasagayam et al., 1992; Cantrell et al., 2003) . The carotenoid family of compounds is divided into two groups, the hydrocarbon "carotenes" and the oxygen-substituted "xanthophylls." Until recently the clinical use of carotenoids as parenteral therapeutic agents has been limited due primarily to their poor aqueous solubility. Many of the early attempts to develop more soluble carotenoid derivatives resulted in compounds that shared a tendency for supramolecular assembly, a form of 3-dimensional aggregation in aqueous solution that limited their ability to participate in oxidation-reduction reactions . Cardax (DDA) is a disodium disuccinate derivative of synthetic astaxanthin (Frey et al., 2004) . This derivative exhibits water ''dispersibility'' of approximately 8.64 mg/ml, allowing for parenteral injection in aqueous formulation. DDA has been well characterized as a direct scavenger of biologically-produced aqueous-phase superoxide anion by electron paramagnetic resonance (EPR) spectroscopy (Cardounel et al., 2003) , and is carried in serum by albumin, allowing it to accumulate in tissues such as the heart after both oral and intravenous administration Gross and Lockwood, 2004; Showalter et al., 2004; Gross and Lockwood, In Press) .
The objective of the present study was to evaluate the ability of DDA to reduce the extent of myocardial damage and activation of the complement system in hearts subjected to ischemia/reperfusion injury. The rabbit in vivo myocardial ischemia/reperfusion model was used to determine whether a 4 day pretreatment regimen with DDA vs. placebo could provide cardioprotection. Previous studies in rats demonstrated a linear correlation between the plasma concentrations of non-esterified astaxanthin measured at the end of reperfusion and the extent of infarct size reduction (Gross and Lockwood, 2004) ; these results were confirmed in a large animal model, the mongrel dog (Gross and Lockwood, In Press) . Based on this information, the current experimental protocol was designed to determine if the cardioprotective effect of DDA involved modulation of the complement cascade, and could potentially reduce the deposition of both C-reactive protein (CRP) and the membrane attack complex (MAC) in the injured myocardium.
This article has not been copyedited and formatted. The final version may differ from this version. Preparation of stock solutions of Cardax (DDA) and placebo for injection. DDA was supplied by Dr. Samuel F. Lockwood (Hawaii Biotech, Inc, Aiea, HI) from a lot previously characterized in detail (Frey et al., 2004) . The crystalline material was dissolved directly in sterile-filtered (0.2 micron Millipore ® filter) deionized water. The maximum aqueous dispersibility of DDA is slightly greater than 10 mM (8.64 mg/ml). Sterile sodium chloride solution (0.9%) for injection was used as the treatment (placebo) for the control group. DDA or placebo solution was administered by slow ear vein injection using an infusion pump set at 1 ml/min. Dosing schedule. Male New Zealand white rabbits (2.3 -2.6 kg) were assigned randomly to two separate groups. Each animal received DDA aqueous formulation (50 mg/kg), or an equal volume of sterile NaCl solution, once per day intravenously. The dose of DDA was selected based on the findings of previous investigations in which it was determined that a dosing regimen over four days produced statistically significant myocardial salvage in Sprague-Dawley rats (41% mean salvage at 50 mg/kg) and mongrel canines (68% mean salvage at 50 mg/kg) after ischemia and reperfusion (Gross and Lockwood, 2004; Gross and Lockwood, In Press) 8 was allowed to reperfuse for a period of three hours before terminating the study.
Tetrazolium method for infarct size determination. At the completion of the 3 hr reperfusion period, the hearts were removed, the aorta was cannulated, and the coronary vascular bed was perfused on a Langendorff apparatus with Krebs-Henseleit buffer at a constant flow of 30 to 32 ml/min. The hearts were perfused with buffer for 10 min to clear the vascular compartment of plasma and blood cellular elements. Fifty milliliters of a 1% solution of triphenyltetrazolium chloride (TTC, Sigma, St. Louis, MO) in phosphate buffer (pH 7.4, 37°C) was perfused through the heart. TTC demarcates the noninfarcted myocardium within the area at risk with a brick red color, indicating the presence of a formazan precipitate resulting from reduction of TTC by dehydrogenases present in viable myocardial tissue. Irreversibly injured tissue, lacking cytosolic dehydrogenases, is unable to form the formazan precipitate and appears pale yellow. Upon completion of the TTC infusion, the left anterior descending coronary artery was ligated at the site identical to that ligated during the induction of regional myocardial ischemia. The perfusion pump was stopped, and 3 ml of a 0.25% solution of Evan's Blue was injected slowly through a side-arm port connected to the aortic cannula. The dye was passed through the heart for 15 sec to ensure its uniform tissue distribution. The presence of Evan's Blue was used to demarcate the left ventricular tissue that was not subjected to regional ischemia, as opposed to the risk region.
The heart was removed from the perfusion apparatus and cut into transverse sections at right angles to the vertical axis. The right ventricle, apex, and atrial tissue were discarded. Both surfaces of each tissue section were traced onto clear acetate sheets. The images were photocopied and enlarged, then digitized using a flatbed scanner. The areas of the normal left ventricle non-risk region, area at risk, and infarct region were determined by calculating the number of pixels occupying each area using Adobe PhotoShop software (Adobe Systems, This article has not been copyedited and formatted. The final version may differ from this version. were taken at the end of reperfusion in selected rabbits (n = 5) treated with DDA, and determined by methods previously described (Osterlie et al., 2000) . Non-esterified, free astaxanthin, in vivo, is generated after cleavage of the water-dispersible disuccinate diester to monosuccinate, and subsequently to non-esterified, free astaxanthin by the intrinsic esterase activity of serum albumin (Curry et al., 1999) , or by non-specific esterase activity in plasma and solid organs (Jensen et al., 1999) . Non-esterified, free astaxanthin then accumulates in myocardium and other tissues after plasma clearance in a dose-dependent manner after both oral (Showalter et al., 2004) and intravenous administration (Gross and Lockwood, 2004; Gross and Lockwood, In Press) .
Tissue concentrations of free astaxanthin reported in nM follows the precedent by Kurihara et al (Kurihara et al., 2002) .
Measurement of cardiac-specific troponin I. Whole blood was drawn at baseline (preischemia) and at the end of reperfusion for the determination of cardiac-specific troponin I (cTnI). Serum levels of the proteins were measured using an enzyme-linked immunosorbent assay (Developed in conjunction with Dr. Chris Chadwick, Life Diagnostic, Inc., West Chester, PA). Briefly, plasma was prepared from whole blood drawn and frozen immediately in liquid nitrogen. The samples were stored at -80°C until the day of the assay when they were thawed over ice and diluted appropriately with sample diluent supplied with each assay kit. Protein concentrations were determined using the OD of each sample as compared to a standard curve.
Immunofluorescent detection of the Membrane Attack Complex (MAC) and C-Reactive
This article has not been copyedited and formatted. The final version may differ from this version. Protein (CRP). The immunofluorescent method for detection of CRP was based on protocols previously developed in our lab (Lauver et al., 2005) . Briefly, tissue samples used for infarct size determination were fixed in 10% buffered formalin immediately after the completion of the experimental protocol. The tissue samples were embedded in paraffin blocks and cut into sections of 2 µm in thickness, which were then mounted on glass slides. Two consecutive sections (mirror images) from a single heart slice were mounted on each slide. The slides were deparaffinized and subjected to antigen unmasking (Vector Laboratories, Burlingame, CA).
After blocking for 30 minutes, primary antibodies were incubated at room temperature in a humidity chamber for 45 minutes. One section per slide was incubated with a chicken anti-rabbit 
Assessment of complement inhibition.
A red blood cell (RBC) lysis assay was used to determine whether the pretreatment with DDA compared to placebo-treated animals was able to inhibit the rabbit complement system. The ex vivo analysis of complement activity is based on the C5b-9-dependent lysis of human red blood cells upon exposure to rabbit plasma.
Complement-mediated RBC hemolysis was assessed by a turbidometric method described previously (Pascual et al., 1990) . The hemolysis assay is an accepted method of assessing the complement titer of plasma or serum samples (Whaley, 1985) . Rabbit plasma was obtained from whole blood samples drawn from rabbits that were pretreated with DDA (50 mg/kg, 4 days, n = 5) or sterile 0.9% sodium chloride solution (4 days, n = 5). After obtaining informed consent, human whole blood for the isolation of red blood cells was obtained by venipuncture of the forearm vein of a healthy, male donor who had not been exposed to any medication for the past seven days. The cells were washed three times in 10 ml phosphate buffered saline (PBS, pH 7.4) and diluted in PBS to achieve a final RBC concentration of 1 × 10 8 cells/ml. 
Results
Hemodynamics. There were no differences in heart rate, blood pressure, or blood gases at baseline or throughout the experimental protocol performed on day 5 between the two groups (data not shown).
Effect of DDA on Myocardial Infarct Size. The mean size of the area at risk expressed as a percentage of the total left ventricle was similar in both groups, indicating that both groups were subjected to similar degrees of ischemia. Rabbits treated with DDA (50 mg/kg/day) exhibited significantly smaller mean infarcts expressed as a percentage of the area at risk (25.8 ± 4.7%) compared with rabbits treated with placebo (52.5 ± 7.5%, **p < 0.01) (Figure 1 ). This represented mean myocardial salvage of 51%.
Plasma and tissue levels of non-esterified, free astaxanthin. The mean plasma concentration
of non-esterified, free astaxanthin at the end of 3 hours of reperfusion is presented in Figure 2 .
Pretreatment with DDA at 50 mg/kg for 4 days resulted in a mean plasma concentration of 222.1 ± 51.0 nM. However, the mean myocardial tissue concentration of DDA was several orders of magnitude greater than that observed in the plasma (10.1 ± 1.6 µM, Figure 2 ), revealing highly favorable mean myocardium/serum ratios in the rabbit after intravenous subchronic administration.
Serum levels of cardiac-specific troponin I. Mean serum concentrations of cTnI were similar at baseline (pre-ischemia) in both treatment groups (0.07 ± 0.04 ng/ml in the vehicle group and 0.12 ± 0.04 ng/ml in the DDA treated animals). DDA treated rabbits exhibited a lower mean cTnI concentration (11.24 ± 4.16 ng/ml) at the end of reperfusion as compared with vehicle controls (19.57 ± 4.56 ng/ml) although this difference was not statistically significant (p = 0.14, Figure 3 ). 
Discussion
It is known that free radical scavengers can attenuate myocardial reperfusion injury by quenching reactive oxygen species that are released upon the reintroduction of blood flow (Kilgore et al., 1994; Lucchesi, 1994) . Perfusion of the rabbit isolated heart in the presence of xanthine and xanthine oxidase (reactive oxygen generating system) results in tissue edema, disorganization of myofilament and mitochondrial swelling in myocytes (Ytrehus et al., 1987; Lucchesi, 1994) . In this study it was observed that the superoxide anion scavenger Cardax (disodium disuccinate astaxanthin, DDA) also reduced the deposition of CRP and the MAC in the infarct-related reperfused myocardium. The results demonstrate a significant mean reduction in the infarct size as a percent of the area at risk in rabbits subjected to 30 minutes of coronary artery occlusion followed by a three hour period of reperfusion. DDA produced a mean myocardial salvage of approximately 51% when the rabbits were dosed with 50 mg/kg daily for four consecutive days. This level of salvage at the 50 mg/kg subchronic intravenous dose is intermediate between that obtained in rats (41% salvage) and mongrel dogs (68%), demonstrating appropriate pharmacokinetic scaling across these mammalian species (Gross and Lockwood, 2004; Gross and Lockwood, In Press) . In addition, we were able to demonstrate a mean reduction in the circulating concentration of the biochemical injury marker, cardiacspecific troponin I. Although these results did not achieve statistical significance, clear evidence of a downward trend in this serum marker of irreversible myocardial tissue injury was obtained.
The reduced statistical power observed in this study versus previous results obtained in our lab for this marker (Lauver et al., 2005 ) may have been due to the curtailed period of reperfusion in the current study. There may have been insufficient time for cTnI to reach peak plasma concentrations in this study.
This article has not been copyedited and formatted. The final version may differ from this version. We were able to achieve plasma concentrations of non-esterified astaxanthin that were roughly equal to those previously found in other species using the same intravenous dosage regimen (Gross and Lockwood, 2004; Gross and Lockwood, In Press) . Unlike these previous experiments a correlation between non-esterified astaxanthin and infarct size could not be determined because only one concentration of the drug was used in the present study. We also observed a marked accumulation of non-esterified astaxanthin in the myocardium (mean > 10 µM) in the rabbits utilized in this study. Rapid plasma clearance of free astaxanthin, and excellent myocardium-and hepatic/serum ratios had previously been demonstrated after oral administration of this compound to black mice (Showalter et al., 2004) .
The current results further demonstrate the favorable pharmacokinetic profile of DDA in mammalian species, suggesting that cardioprotection may be facilitated after parenteral administration in other species as well.
Along with the generation of reactive oxygen species, the activation of the complement system serves an integral role in myocardial reperfusion injury (Lucchesi, 1994) . Therefore we sought to also investigate the effects of DDA on the tissue deposition of CRP and the terminal complex (C5b-9), both of which are expressed in the process of tissue undergoing the inflammatory response after ischemia/reperfusion.
CRP is an acute phase protein known to be a highly sensitive, but nonspecific, marker of inflammation. The plasma concentration of CRP is increased in the presence of chronic inflammation and there is a relationship between the circulating plasma concentration and subsequent cardiovascular events (de Beer et al., 1982; Yeh et al., 2001; Ridker et al., 2005) .
CRP is known to be involved in the local activation of the complement system (Volanakis, 1982; Diaz Padilla et al., 2003; Nijmeijer et al., 2003) . Our previous studies demonstrated that the This article has not been copyedited and formatted. The final version may differ from this version. crystalloid perfused isolated heart itself is capable of expressing mRNA and the rapid expression of complement proteins as well as the membrane attack complex in response to ischemia/reperfusion injury (Yasojima et al., 1998) . Furthermore, free radical-mediated (xanthine / xanthine oxidase) myocardial tissue injury was accompanied by the tissue expression of the MAC (Tanhehco et al., 2000) . Using an immunofluorescent method to determine the presence of tissue-bound CRP and the MAC, we were able to show that DDA significantly reduced the deposition of both CRP and MAC, which were found localized within the area of infarction. Subsequently we measured the complement activity in the plasma and found that DDA significantly reduced the activity of the complement system in plasma samples obtained from rabbits dosed with DDA when compared to placebo treated animals. To our knowledge, this anti-inflammatory mechanism for the novel astaxanthin diester utilized in the current study is the first report of such activity in the setting of ischemia/reperfusion injury.
Further investigations are warranted in order to more accurately define the anticomplement (and thus anti-inflammatory) effects of DDA. Previous studies have suggested a link between retinoid-like compounds and the expression of soluble complement receptor type 1 (sCR1) (Funkhouser and Vik, 1999 Figure 1 . Effects of DDA on myocardial infarct size after 30 min of left anterior descending coronary artery occlusion and 3 h of reperfusion compared with vehicle. DDA (50 mg/kg) was administered daily for 4 days prior to the experimental occlusion on day 5. The mean areas at risk were similar between groups, indicating that the degree of the ischemic insult was similar.
Legends for Figures
Infarct size after ischemia/reperfusion is expressed as a percentage of the area at risk. The infarct region is decreased significantly in the group treated with DDA compared with vehicle.
Values are expressed as mean ± S.E.M.; saline group, n = 9 (white bars); DDA group, n = 9
(black bars); ** p < 0.01 versus saline. saline group, n = 9 (white bars); DDA group, n = 9 (black bars). 
